Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fulgent GeneticsFRA:7F0 60 EV-to-EBIT is -2.85 as of Aug. 13, 2026. GuruFocus rates FRA:7F0 with a GF Score™ of 60/100 and a GF Value™ of €21.06 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Fulgent Genetics ranks worse than 952380% on this metric.
The historical rank and industry rank for Fulgent Genetics's EV-to-EBIT or its related term are showing as below:
FRA:7F0'
s EV-to-EBIT Range Over the Past 10 Years
Min: -817.49 Med: -3.57 Max: 592.59
Current: -2.83
During the past 12 years, the highest EV-to-EBIT of Fulgent Genetics was 592.59. The lowest was -817.49. And the median was -3.57.
FRA:7F0's EV-to-EBIT is ranked worse than 100% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.25
vs FRA:7F0: -2.83
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Fulgent Genetics's Enterprise Value for the quarter that ended in Jun. 2026 was €272.7 Mil.
Fulgent Genetics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-79.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics EV-to-EBIT Related Terms
Fulgent Genetics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7F0 vs MYGN, CSTL, BDSX: EV-to-EBIT Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's EV-to-EBIT falls into.
Fulgent Genetics's current Enterprise Value is €226.6 Mil.
Fulgent Genetics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-79.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics (FRA:7F0) has a EV-to-EBIT of -2.85 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fulgent Genetics and its competitors. According to the industry distribution chart, Fulgent Genetics ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry.
Is Fulgent Genetics' EV-to-EBIT too high?
Fulgent Genetics' current EV-to-EBIT is -2.85. Based on the distribution chart, Fulgent Genetics ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Fulgent Genetics has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' EV-to-EBIT compare to MYGN and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #999999 out of 105 companies for EV-to-EBIT. This places Fulgent Genetics in the lower half of its industry. The industry median EV-to-EBIT is 24.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.25, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fulgent Genetics and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulgent Genetics's current EV-to-EBIT is -2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FRA:7F0) is currently considered Modestly Undervalued. The stock's GF Value™ is €21.06, compared to a current price of €16.40 — trading 22.1% below its estimated fair value. The current EV-to-EBIT is -2.85. Fulgent Genetics' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Fulgent Genetics (FRA:7F0), the current EV-to-EBIT is -2.85 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FRA:7F0) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of €16.40 is trading 22.1% below its estimated GF Value™ of €21.06.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FRA:7F0:
EV-to-EBIT: -2.85
GF Value™: €21.06 vs. price of €16.40 (22.1% below fair value)
No single metric tells the full story. See the FRA:7F0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
60GF Score
Get the complete analysis for FRA:7F0
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7F0 has been successfully added to your 
